Study aim: Assessment of the effect of Iranian medicine product, SINA anti-flu, on the symptoms of patients with covid-19 (Coronavirus 19 disease) Design: This clinical trial has control group, and with parallel groups, double blinded, randomized, phase 2 to 3 and is performed on 80 patients. Randomization method will be blocked randomization (Quaternary random blocks). Settings and conduct: Patients in the drug group take the Iranian traditional drug for ten days and 4 times from syrup and 2 times from drop daily In addition to the usual medicines (According to the protocol of the Ministry of Health). Patient in control group use routine treatment and placebo. The study is performed in Baqiyatallah Hospital. Participants/Inclusion and exclusion criteria: Inclusion criteria: Male or female patients 18 years old and older with COVID-19, positive coronavirus 19 PCR, Ground glass view at low-dose CT scan, Arterial oxygen saturation less than 93%, Consciously completed consent form completed by the patient or the patient's supervisor. Exclusion criteria: History of pulmonary malignancy, History of asthma or COPD, History of Disabling disease or malignancy, Liver or kidney disorders. Intervention groups: Intervention groups will be two ones.Patients in the intervention group will receive the intervention drug (syrup & drop) in addition to the routine treatment, but in control group, they will receive placebo in addition to the routine treatment. Main outcome variables: 3D lung CT Scan, dyspnea, cough, arterial oxygen saturation, PCR, CBC diff